IP Library Granted Patent US 11,279,784
Granted Patent B2
US 11,279,784 · App. 16/437,061 · Granted Mar 22, 2022

Preparations of meta-iodobenzylguanidine and precursors thereof

Inventors: Jason Moss (New York, NY); Machinani Rao (New York, NY)
Assignee: MOLECULAR INSIGHT PHARMACEUTICALS, INC.
C08F230/04A61K51/0406C07C279/06A61K31/155A61P35/00C07C277/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,279,784
App. No.
16/437,061
Granted
Mar 22, 2022
Kind
B2
Abstract

The present disclosure provides purified forms of iobenguane and preparations of a precursor to iobenguane, such as a polymer, the polymer comprising a monomer of formula (I) or a pharmaceutically acceptable salt thereof, the preparation comprising leachable tin at a level of 0 ppm to 850 ppm.

Claims (24)

1. A method for preparing a purified composition of a polymer comprising a monomer of formula (I):

or a pharmaceutically acceptable salt thereof,

the method comprising the steps of:

counter ion exchange of a hydrochloric acid form of the monomer of formula (I) with sodium acetate to thereby provide a preparation comprising the monomer of formula (I) in the form of a HOAc salt;

a first solvent treating step, comprising contacting the preparation with aqueous alcohol, and then removing substantially all of the aqueous alcohol;

a second solvent treating step, comprising contacting preparation with anhydrous alcohol, and then removing substantially all of the anhydrous alcohol so that a solvent-depleted material comprising the polymer is generated; and

subjecting the solvent-depleted material to vacuum, and to a temperature within a range of about 30° C. to about 50° C., the subjecting being performed under conditions and for a time sufficient to thereby provide the purified composition of the polymer, or pharmaceutically acceptable salt thereof;

wherein no more than 150 ppm of leachable tin is present in the purified composition of the polymer.

2. The method of claim 1 , wherein the aqueous alcohol comprises ethanol.

3. The method of claim 1 , wherein the anhydrous alcohol is or comprises ethanol.

4. The method of claim 1 , wherein the aqueous alcohol is or comprises ethanol and the anhydrous alcohol is or comprises ethanol.

5. The method of claim 1 , the purified composition comprising less than 1.5 wt % water relative to the wt % of the composition.

6. The method of claim 1 , the purified composition comprising less than 1.0 wt % water relative to the wt % of the composition.

7. The method of claim 1 , further comprising a step of: storing the purified composition under an inert gas.

8. The method of claim 1 , wherein the purified composition comprises less than 2.0 wt % water relative to the wt % of the purified composition.

9. The method of claim 3 , wherein the first solvent treating step comprises treating the preparation with aqueous ethanol.

10. The method of claim 9 , wherein the second solvent treating step comprises treating the preparation with absolute ethanol.

11. The method of claim 1 , wherein the removal of substantially all of the aqueous alcohol or the anhydrous alcohol comprises a first removal step of drying the preparation at ambient temperature and pressure with a flow of nitrogen.

12. The method of claim 11 , wherein the removal of substantially all of the aqueous alcohol or the anhydrous alcohol comprises a first removal step of drying the preparation at ambient temperature and pressure with a flow of nitrogen and then further comprises a second removal step of drying the preparation at ambient temperature under vacuum with a flow of nitrogen.

13. The method of claim 1 , wherein the purified composition comprises not more than about 120 ppm of leachable tin.

14. The method of claim 1 , wherein the purified composition comprises not more than about 90 ppm of leachable tin.

15. The method of claim 1 , wherein the purified composition comprises not more than about 50 ppm of leachable tin.

16. The method of claim 1 , wherein the subjecting being performed under conditions and for a time sufficient so that not more than about 0.5 wt % organic solvent relative to the wt % of the composition is present.

17. The method of claim 1 , wherein the subjecting being performed under conditions and for a time sufficient so that not more than about 0.3 wt % organic solvent relative to the wt % of the composition is present.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Dec 2, 2022
From: WELLS FARGO BANK, N.A.
To: PROGENICS PHARMACEUTICALS, INC.; MOLECULAR INSIGHT PHARMACEUTICALS, INC.; PSMA DEVELOPMENT COMPANY, LLC
Reel/Frame 062047/0915 →
SECURITY INTEREST Recorded Dec 2, 2022
From: LANTHEUS MEDICAL IMAGING, INC.; MOLECULAR INSIGHT PHARMACEUTICALS, INC.; PSMA DEVELOPMENT COMPANY, LLC; PROGENICS PHARMACEUTICALS, INC.
To: CITIZENS BANK, N.A.
Reel/Frame 062047/0960 →
SECURITY AGREEMENT Recorded Aug 19, 2020
From: PROGENICS PHARMACEUTICALS, INC.; MOLECULAR INSIGHT PHARMACEUTICALS, INC.; PSMA DEVELOPMENT COMPANY LLC
To: WELLS FARGO BANK, N.A.
Reel/Frame 053538/0666 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 12, 2019
From: MOSS, JASON; RAO, MACHINANI
To: MOLECULAR INSIGHT PHARMACEUTICALS INC.
Reel/Frame 049443/0815 →
Continuity (4)
Division 14921898 · Oct 23, 2015
Provisional Application 62069029 · Oct 27, 2014
Provisional Application 62068598 · Oct 24, 2014
Related Publication 20190367653A1 · Dec 5, 2019